Medications for Neurofibromatosis
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Neurofibromatosis.
Found 2 Approved Drugs for Neurofibromatosis
Koselugo
Generic Name
Selumetinib
Koselugo
Generic Name
Selumetinib
Form: Granule, Capsule
Method of administration: Oral
FDA approval date: April 16, 2020
Classification: Kinase Inhibitor
KOSELUGO is indicated for the treatment of pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). KOSELUGO is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). ( 1 )
Gomekli
Generic Name
Mirdametinib
Gomekli
Generic Name
Mirdametinib
Form: Tablet, Capsule
Method of administration: Oral
FDA approval date: February 11, 2025
GOMEKLI is indicated for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. GOMEKLI is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. ( 1 )
Showing 1-2 of 2
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances